Replies to post #392453 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"The fact is that only 7% of the moderate-to-severe COVID-19 patients in the study died, whether they were on brilacidin or not.

So hurray for standard of care!"

That realization only came to me yesterday (duh!).
Another post referred to the March 7th PR which says:
"There was also no difference in mortality between active and placebo, with both groups experiencing low mortality rates (7 percent) compared to other studies that evaluated patients with moderate-to-severe COVID-19."

It's hard to assess whether the 7% rate was "low" due to the effectiveness of the standard of care or the inclusion/exclusion criteria of the other studies. It's definitely lower than the rate for patients who were simply "hospitalized with moderate-to-severe covid", but that's not a reasonable comparison.
There isn't enough information in the second half of the quote from the PR to reach any particular conclusion, is there? I think the only reliable takeaway from the full sentence is that there was no difference in mortality between those treated with brilacidin and SOC and those treated with a placebo and SOC...the rest is incomplete window dressing.

[loanranger]

I failed to link that March 7th press release and I should have....it has details in it that didn't get much attention here and that might be worth reviewing:
http://www.ipharminc.com/press-release/2022/3/7/innovation-pharmaceuticals-reports-additional-findings-based-on-review-of-brilacidin-phase-2-covid-19-trial-results-and-compassionate-use-cases

For example re: "most COVID-19 patients will get heparin anyway" there's this:

Standard-of-Care (SoC)
Review of Brilacidin Phase 2 COVID-19 trial data showed most patients (>87 percent) received treatment with systemic corticosteroids (generally at high doses, and for long durations), and treatment with mucolytics (>82 percent), antivirals (>68 percent), analgesics (>56 percent), immunosuppressants (>45 percent), anti-thrombotic agents (>97 percent), and other supportive medications as SoC for COVID-19.

I may be mistaken but I think that anti-thrombotic agent is likely heparin.
"Only" 68%+ patients got antivirals. Doesn't that mean that 1/3 of them DIDN'T get Remdesivir?
The Standard of Care seems to have been anything but standard.

"Such implementation of a more aggressive COVID-19 SOC, as has been reported by other companies evaluating COVID-19 trial results, may have contributed to an overall lessening of observable Brilacidin treatment effects."
(In other words "So hurray for standard of care!".)